ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0341

Inhibition of miR-155 Ameliorates AKI by Protecting Telomeres and Reducing DNA Damage of Renal Tubular Cells

Session Information

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms


  • Yin, Qing, Southeast University, Nanjing, Jiangsu, China
  • Wang, Bin, Southeast University, Nanjing, Jiangsu, China
  • Liu, Bi-Cheng, Southeast University, Nanjing, Jiangsu, China

Acute kidney injury (AKI) is associated with significant morbidity and mortality, and currently there is no therapy to prevent or treat established AKI. miR-155 is significantly up-regulated in diabetic nephropathy, IgA nephropathy, bilateral renal ischemia-reperfusion injury (IRI) or drug-induced AKI. However, the molecular mechanism of miR-155 in AKI remains to be studied.


We subjected miR-155-/- mice and wild-type controls, as well as human proximal tubule cells, to cisplatin-induced AKI models. We assessed kidney function and injury with standard techniques and measured telomere by the fluorescence in situ hybridization.


The expression level of miR-155 was upregulated in both cisplatin-induced AKI mice model and cisplatin-treated HK2 cells. Inhibition of miR-155 expression protected cisplatin-induced AKI both in vivo and in vitro. Compared with wild-type mice, miR-155-/- mice had reduced mortality, improved renal function and pathological damage after cisplatin intervention. Moreover, inhibition of miR-155 expression decreased cells apoptosis and suppressed DNA damage. Additionally, we found that miR-155 efficiently regulates TRF1 expression by targeting a partially conserved sequence motif in the TRF1 3’UTR. Inhibition of miR-155 enhanced the expression of TRF1 and reduced the telomere DNA damage induced by cisplatin. In addition, CDK12 had also been identified as a novel target of miR-155. Inhibition of miR-155 increased the expression of CDK12, and reduced DNA damage and maintain genome stability.


We demonstrated that inhibition of miR-155 ameliorates AKI involving the targeting and regulation of TRF1 and CDK12, indicating a novel regulatory mechanism and elucidating a potential target for cisplatin induced AKI treatment.


  • Government Support – Non-U.S.